UnitedHealthcare and Medtronic

Working Together to Support People with Diabetes

Safety and a focus on helping individuals with diabetes avoid dangerous highs and lows in their sugar levels were the key factors in our decision to make the MiniMed™ 670G system from Medtronic® our preferred pump for adults and children age 7 and older who receive a prescription for an insulin pump for the first time.

What members need to know:

1. Children currently using a non-Medtronic pump may continue to do so.
   
   Any children currently using a non-Medtronic pump may remain on that pump as long as they wish, and we have always offered a review process to preserve access to other pumps when a physician may recommend an alternative choice. Pediatric patients who are currently using a non-Medtronic pump may remain on that pump in conjunction with the physician’s treatment plan.

2. There is no change to coverage.
   
   There is no change to coverage for members currently on an insulin pump and receiving supplies. Similarly, there is no change for the use of non-durable insulin pumps such as tubeless pumps. Members should call the number on their ID card with questions.

3. Nearly all members are already using a MiniMed™ device.
   
   The vast majority – nearly 9 in 10 – of all UnitedHealthcare members using insulin pumps today use a MiniMed™ device from Medtronic.

4. There is continued access to other pumps through our clinical review process.
   
   To preserve access to other pumps, we will continue to have a clinical review process in place for prescribing physicians and members who feel a non-Medtronic device may be preferred. Our goal is to offer members a better care experience by providing access to advanced diabetes technology and comprehensive support services.
Clinical Benefits

MiniMed™670G is the safest and most effective

Studies have shown the MiniMed™670G system from Medtronic is the safest and most effective on the market.¹ A clinical trial showed patients spent more time in range, experienced less glycemic variability and less exposure to hypoglycemia and hyperglycemia, and experienced reduced A1C compared to baseline data using sensor-augmented pumps.¹

- The percentage of Time in Range increased from 56.2 percent to 65.0 percent.

FDA Approved

The FDA in 2018 approved the MiniMed pump for use by children ages 7 and up, based on positive results from a pediatric clinical trial conducted by Medtronic, which demonstrated:

- The percentage of Time in Range increased from 56.2 percent to 65.0 percent.
- A1C levels were also reduced from 7.9 percent to 7.5 percent.
- There were no incidences of diabetic ketoacidosis (DKA) in the study phase in Auto Mode and no severe hypoglycemic or serious device-related adverse events were reported.

Preventable Admissions Declining

UnitedHealthcare has seen 27 percent fewer preventable hospital admissions among 6,000 of its plan participants on Medtronic insulin pumps when compared to individuals on multiple daily injections of insulin (MDI). This preliminary data reflects first year results of a multiyear initiative between UnitedHealthcare and Medtronic.


"The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, age 7 and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. A confirmatory finger stick test via the CONTOURNEST LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOURNEST LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to help ensure the glucose result shown agrees with the glucose results shown on the CONTOURNEST LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.

WARNING: Medtronic performed an evaluation of the MiniMed™ 670G system and determined that it may not be safe for use in children under age 7 because of the way that the system is designed and the daily insulin requirements. Therefore, this device should not be used in anyone under age 7. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely.